Key result
Poor overall cardiovascular risk factor control was present in 51% of men with prostate cancer and was significantly associated with not taking a statin (OR 2.55; 95% CI 2.00-3.26).
Why the study?
Cardiovascular disease incidence is higher in men with prostate cancer than without, motivating an assessment of poor cardiovascular risk factor control in this population.
Observational
Odds Ratio: 2.55 (95% CI 2–3.26)
Poor control of modifiable cardiovascular risk factors is highly prevalent in men with prostate cancer, highlighting a significant gap in cardio-oncology care.
Background: Cardiovascular disease (CVD) incidence is higher in men with prostate cancer (PC) than without. Objectives: We describe the rate and correlates of poor cardiovascular risk factor control among men with PC. Methods: 120 mm Hg if known CVD or FRS ≥15, and ≥130/80 mm Hg if diabetic), and waist:hip ratio >0.9. Results: Among participants (9% with metastatic PC and 23% with pre-existing CVD), 99% had ≥1 uncontrolled cardiovascular risk factor, and 51% had poor overall risk factor control. Not taking a statin (odds ratio [OR]: 2.55; 95% CI: 2.00-3.26), physical frailty (OR: 2.37; 95% CI: 1.51-3.71), need for BP drugs (OR: 2.36; 95% CI: 1.84-3.03), and age (OR per 10-year increase: 1.34; 95% CI: 1.14-1.59) were associated with poor overall risk factor control after adjustment for education, PC characteristics, androgen deprivation therapy, depression, and Eastern Cooperative Oncology Group functional status. Conclusions: Poor control of modifiable cardiovascular risk factors is common in men with PC, highlighting the large gap in care and the need for improved interventions to optimize cardiovascular risk management in this population.
No takes yet. Share an insight, caveat, or question.
Klimis et al. (2023) conducted an observational in Prostate cancer. Not taking a statin vs. Taking a statin was evaluated on Poor overall cardiovascular risk factor control (OR 2.55, 95% CI 2.00-3.26). Poor overall cardiovascular risk factor control was present in 51% of men with prostate cancer and was significantly associated with not taking a statin (OR 2.55; 95% CI 2.00-3.26).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: